Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 13/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.43 |
| ▸ | TDP2 | O95551 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | APAF1 | O14727 | 2/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | GALK1 | P51570 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.42 |
| ▸ | LMNA | P02545 | 11/20 | 0.42 |
| ▸ | HPGD | P15428 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 7/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625662 | 0.84 | SPR (0.53) | SPRMAPTKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL1627845 | 0.84 | SPR (0.68) | SPRMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL1627764 | 0.84 | SPR (0.58) | SPRMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL1625313 | 0.84 | SPR (0.46) | SPRMAPTKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL1625808 | 0.84 | SPR (0.55) | SPRMAPTKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL1626362 | 0.84 | SPR (0.48) | SPRMAPTKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL1626679 | 0.83 | SPR (0.41) | SPRMAPTKDM4ETDP2L3MBTL1 | |
| SCHEMBL1626733 | 0.82 | SPR (0.44) | SPRMAPTKDM4EL3MBTL1MEN1 | |
| SCHEMBL1627752 | 0.82 | SPR (0.48) | SPRMAPTKDM4ETDP2L3MBTL1 | |
| SCHEMBL1626606 | 0.82 | SPR (0.52) | SPRMAPTKDM4EL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928139-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-7635715-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | EGLN2, EGLN3, HIF1AN | SPR 754/4885MAPT 4316/4885KDM4E 977/4885 |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | EGLN2, EGLN3, HIF1AN | SPR 754/4885MAPT 4316/4885KDM4E 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.